BusinessNovan Presents Preclinical Data from Inflammatory Skin Diseases ProgramBy Nasdaq OMXApr 27, 2017, 1:05 PM UTC
BusinessGalectin Therapeutics Reports 2016 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 28, 2017, 12:31 PM UTC
BusinessGR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema)By Nasdaq OMXMar 14, 2017, 12:47 PM UTC
BusinessMatriSys Bioscience announces today publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitisBy Nasdaq OMXFeb 22, 2017, 10:39 PM UTC
BusinessGalectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin DiseasesBy Nasdaq OMXNov 10, 2016, 1:00 PM UTC
